Patricia Bricmont

Phase 1, open-label, dose-escalation, and pharmacokinetic study of STAT3 inhibitor OPB-31121 in subjects with advanced solid tumors

Johanna C. Bendell, David S. Hong, Howard A. Burris et al. · Cancer Chemotherapy and Pharmacology · 2014 · 111 citations

Medicine, Pharmacokinetics, Pharmacology +5

Pharmacokinetics, tolerability and safety of aripiprazole once-monthly in adult schizophrenia: An open-label, parallel-arm, multiple-dose study

Suresh Mallikaarjun, John M. Kane, Patricia Bricmont et al. · Schizophrenia Research · 2013 · 107 citations

Pharmacy, Pharmacokinetics, Pharmacology +16

Pharmacokinetics, Pharmacodynamics, and Safety of Tolvaptan, a Nonpeptide AVP Antagonist, During Ascending Single‐Dose Studies in Healthy Subjects

Susa E. Shoaf, Zhao Wang, Patricia Bricmont et al. · The Journal of Clinical Pharmacology · 2007 · 87 citations

Medicine, Pharmacokinetics, Pharmacology +13

Relationship Between Plasma Concentrations Of 3'-Deoxy-3'-Fluorothymidine (Alovudine) And Antiretroviral Activity In Two Concentration-Controlled Trials

Charles Flexner, Caroline van der Horst, M. A. Jacobson et al. · The Journal of Infectious Diseases · 1994 · 77 citations

Medicine, Pharmacokinetics, Pharmacology +13

Effects of CYP3A4 inhibition and induction on the pharmacokinetics and pharmacodynamics of tolvaptan, a non‐peptide AVP antagonist in healthy subjects

Susan E. Shoaf, Patricia Bricmont, Suresh Mallikaarjun · British Journal of Clinical Pharmacology · 2011 · 70 citations

Medicine, Pharmacokinetics, Pharmacology +15